share_log

JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45

JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45

JMP證券維持Protagonist Therapeutics的市場跑贏大盤,將目標股價上調至45美元
Benzinga ·  05/08 14:09

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $42 to $45.

JMP證券分析師喬納森·沃勒本維持Protagonist Therapeutics(納斯達克股票代碼:PTGX)的市場表現跑贏大盤,並將目標股價從42美元上調至45美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論